AIM AIM ImmunoTech Inc.
Company Analysis
Latest News
AIM ImmunoTech Amends Bylaws to Adopt 'Majority of Votes Cast' Voting Standard
AIM ImmunoTech Inc. announced that its Board of Directors approved an amendment to the company's bylaws, effective June 9, 2026, which changes the voting...
AIM ImmunoTech's Fire-Sale Capital Raise Wipes Out 84% of Shareholder Value — Can This Biotech Survive Its Own Desperation?
Shares of AIM ImmunoTech (AIM) cratered 83.7% in a single session, plunging from $2.79 to $0.45, after the company announced a deeply discounted capital raise...
🔴 AIM ImmunoTech Inc is trading 84% down today following heavy dilution from a $2.65M equity offering
AIM ImmunoTech Inc is trading 84% down at $0.45 following an extreme dilution-driven selloff tied to its latest capital raise. • The company announced a $2.65...
🔴 AIM ImmunoTech Inc is trading 5.5% down today extending losses after a massive dilution-driven selloff
AIM ImmunoTech Inc is trading 5.5% down at $0.38 in pre-market, continuing a sharp downward trend following an 85% plunge on June 9. • The selloff was...
🔴 AIM ImmunoTech Inc is trading 85.4% down today after $2.65M at-market financing announcement
AIM ImmunoTech Inc is trading 85.4% down at $0.40 after announcing a $2.65 million at-market financing on June 9, 2026. • The financing was priced at $0.5189...
AIM ImmunoTech Highlights Ampligen's Potential as an Ebola Virus Disease Therapeutic
AIM ImmunoTech Inc. released an investor video presentation and press release on June 4, 2026, detailing previously published pre-clinical data on its lead...
🔴 AIM ImmunoTech Inc is trading 11.4% down today as profit-taking continues after trial-driven surge
AIM ImmunoTech Inc is trading 11.4% down at $0.73 as the sharp pullback from last week’s trial-fueled spike continues. • The stock more than doubled recently...
🔴 AIM ImmunoTech Inc is trading 13.3% down today as profit-taking extends a pullback from its recent trial-driven surge
AIM ImmunoTech Inc is trading 13.3% down at $0.72 in pre-market, extending a sharp pullback from its recent speculative surge. • The stock more than doubled...
🔴 AIM ImmunoTech Inc is trading 7.2% down today as profit-taking continues after pancreatic cancer trial rally
AIM ImmunoTech Inc is trading at $0.77 (7.2% down) in after-hours trading as the stock enters a sharp giveback phase following a recent speculative surge. •...
AIM ImmunoTech Soars Then Stumbles on Pancreatic Cancer Trial News — Can a 20-Employee Biotech Survive the Road to Phase 3?
Shares of AIM ImmunoTech whipsawed this week, surging more than 120% on June 1 before pulling back 13.4% to $0.78 the next day, as traders locked in gains from...
🔴 AIM ImmunoTech Inc is trading 13.4% down today as shares pull back following a sharp rally on trial enrollment news
AIM ImmunoTech Inc is trading at $0.78 (13.4% down) as the stock experiences a pullback following a significant two-day surge tied to its pancreatic cancer...
🟢 AIM ImmunoTech Inc is trading 33.3% up today after announcing early completion of enrollment for its Phase 2 pancreatic cancer trial
AIM ImmunoTech Inc is trading at $0.54 (33.3% up) after announcing a significant milestone in its pancreatic cancer program. • The company announced it has...
🟢 AIM is trading 9.8% up today as volatile rebound continues in thinly traded name
AIM is trading at $0.45 (+9.8%) in pre-market as the stock continues a volatile rebound following recent pressure. • The move appears driven by short-term...
🔴 AIM is trading 10.96% down today on profit-taking after a sharp two-day rebound
AIM is trading 10.96% down at $0.39 on short-term profit-taking following a significant two-day rally. • The pullback follows a rapid move from approximately...
🔴 AIM is trading 10.4% down today on potential profit-taking after a sharp two-day rebound
AIM is trading at $0.39 (10.4% down) today as the stock faces potential profit-taking following a sharp two-day rebound earlier in the week. * No fresh...